Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study

21Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: In the Danish population, we examined whether patients treated with thiopurines, methotrexate, systemic corticosteroids, anti-tumour necrosis factor (TNF)-α agents, anti-interleukin therapeutic agents, selective immunosuppressive agents and cyclosporine/tacrolimus had an increased risk of hospitalization for COVID- 19, compared to the background population. Methods: A nationwide cohort study including all people alive in Denmark on 1 March 2020. Exposed patients constituted those exposed to thiopurines (n = 5484), methotrexate (n = 17 977), systemic corticosteroids (n = 55 868), anti-TNF-α agents (n = 17 857), anti-interleukin therapeutic agents (n = 3744), selective immunosuppressive agents (n = 3026) and cyclosporine/tacrolimus (n = 1143) in a period of 12 months prior to 1 March 2020 (estimated time of outbreak in Denmark). We estimated the adjusted risk of hospitalization for COVID-19 for patients treated with the above-mentioned categories of medications, compared to the rest of the population. Results: The adjusted odds ratios of hospitalization in patients treated with corticosteroids and cyclosporine/tacrolimus were 1.64 (95% confidence interval [CI] 1.35 to 2.00) and 4.75 (95% CI 1.96 to 11.49), respectively. The risks of hospitalization in patients treated with thiopurines, methotrexate, and anti-TNF-α agents, were 1.93 (95% CI 0.91 to 4.08), 0.74 (95% CI 0.43 to 1.28), 1.00 (95% CI 0.52 to 1.94), respectively. The number of outcomes in patients treated with anti-interleukin therapeutic agents and selective immunosuppressive agents was too small for analysis. Conclusion: Patients treated with systemic corticosteroids and cyclosporine/tacrolimus had a significantly increased risk of being hospitalized for COVID-19. Our study does not uncover whether the increased risk is related to the drug itself, the underlying condition for which the patient is treated or other factors.

References Powered by Scopus

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

40157Citations
N/AReaders
Get full text

A pneumonia outbreak associated with a new coronavirus of probable bat origin

15321Citations
N/AReaders
Get full text

The Danish National patient registry: A review of content, data quality, and research potential

3363Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments

48Citations
N/AReaders
Get full text

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

27Citations
N/AReaders
Get full text

Vaccination and their importance for lung transplant recipients in a COVID-19 world

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Nørgård, B. M., Nielsen, J., Knudsen, T., Nielsen, R. G., Larsen, M. D., Jølving, L. R., & Kjeldsen, J. (2021). Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. British Journal of Clinical Pharmacology, 87(4), 2111–2120. https://doi.org/10.1111/bcp.14622

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

62%

Researcher 9

35%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

50%

Nursing and Health Professions 6

21%

Pharmacology, Toxicology and Pharmaceut... 5

18%

Social Sciences 3

11%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 6

Save time finding and organizing research with Mendeley

Sign up for free